Elsiglutide is a peptide derivative of glucagon-like peptide 2 (GLP-2).1 It increases jejunum and ileum crypt depth and villus height without disrupting gut microbiota diversity in rats when administered at a dose of 0.9 mg/kg four days per week. Elsiglutide decreases diarrhea severity and incidence induced by the dual inhibitor of EGFR and HER2 lapatinib in rats. It prevents lapatinib-induced loss of body weight in rats.
References:
[1]. Mayo, B.J., Secombe, K.R., Wignall, A.D., et al.The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in ratsCancer Chemother. Pharmacol.85(4)793-803(2020).
















